Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Condition: Hemorrhagic Stroke
Drug: Warfarin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Bleeding Complications Associated with Warfarin Treatment in Ischemic Stroke Patients with Atrial Fibrillation: A Population-Based Cohort Study
Background: Bleeding events are the major obstacle to the widespread use of warfarin for secondary stroke prevention. Previous studies have not examined the use of risk stratification scores to estimate lifetime bleeding risk associated with warfarin treatment in a population-based setting. The purpose of this study is to determine the lifetime risk of bleeding events in ischemic stroke patients with atrial fibrillation (AF) undergoing warfarin treatment in a population-based cohort and to evaluate the use of bleeding risk scores to identify patients at high risk for lifetime bleeding events.Methods: The resources of the R...
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2013 Category: Neurology Authors: Raymond C.S. Seet, Alejandro A. Rabinstein, Teresa J.H. Christianson, George W. Petty, Robert D. Brown Tags: Original Articles Source Type: research
Tissue Plasminogen Activator Thrombolytic Therapy for Acute Ischemic Stroke in 4 Hospital Groups in Japan
In October 2005 in Japan, the recombinant tissue plasminogen activator (tPA) alteplase was approved for patients with acute ischemic stroke within 3 hours of onset at a dose of 0.6 mg/kg. The present study was undertaken to assess the safety and efficacy of alteplase in Japan. Between October 2005 and December 2009, a total of 114 consecutive patients admitted to 4 hospitals received intravenous tPA within 3 hours of stroke onset. Clinical backgrounds and outcomes were investigated. The patients were divided into 2 chronological groups: an early group, comprising 45 patients treated between October 2005 and December 2007,...
Source: Journal of Stroke and Cerebrovascular Diseases - October 4, 2011 Category: Neurology Authors: Syoichiro Kono, Kentaro Deguchi, Nobutoshi Morimoto, Tomoko Kurata, Shoko Deguchi, Tohru Yamashita, Yoshio Ikeda, Tohru Matsuura, Hisashi Narai, Nobuhiko Omori, Yasuhiro Manabe, Taijyun Yunoki, Yoshiki Takao, Sanami Kawata, Kenichi Kashihara, Koji Abe Tags: Original Articles Source Type: research
Comparison of primary and secondary stroke prevention in patients with nonvalvular atrial fibrillation: Results from the RAFFINE registry
Atrial fibrillation (AF) is a predictor of severe stroke and early death in acute ischemic stroke patients.1 The prevalence of AF has increased as the Japanese population has aged.2 AF has been more common among patients with ischemic stroke than previously reported.3 In particular, AF patients with a history of stroke or TIA have had higher risks for stroke, hemorrhagic events, and death compared to those without.4,5 In these previous studies, most patients received warfarin for anticoagulation therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - November 7, 2022 Category: Neurology Authors: Kazuo Yamashiro, Ryota Tanaka, Sakiko Miyazaki, Katsumi Miyauchi, Hidemori Hayashi, Yuji Nishizaki, Shuko Nojiri, Satoru Suwa, Masataka Sumiyosi, Yuji Nakazato, Takao Urabe, Nobutaka Hattori, Tohru Minamino, Hiroyuki Daida Source Type: research
Warfarin versus Aspirin for Prevention of Stroke in Heart Failure: A Meta-analysis of Randomized Controlled Clinical Trials
Conclusions: Compared with aspirin, warfarin reduced the risk of stroke while conferring an increased risk of major hemorrhage. Warfarin does not increase mortality or confer an increased risk of ICH compared with aspirin.
Source: Journal of Stroke and Cerebrovascular Diseases - November 21, 2012 Category: Neurology Authors: Gyanendra Kumar, Munish Kumar Goyal Tags: Original Articles Source Type: research
Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study
In the acute phase of cardioembolic stroke in patients with nonvalvular atrial fibrillation (NVAF), the recurrence rate is high. Nonvitamin K antagonist oral anticoagulants may be appropriate for prevention of early recurrence because they have a much lower risk of hemorrhagic stroke than warfarin.
Source: Journal of Stroke and Cerebrovascular Diseases - March 14, 2016 Category: Neurology Authors: Masahiro Yasaka, Kazuo Minematsu, Kazunori Toyoda, Hiroshi Yamagami, Shinichi Yoshimura, Takehiko Nagao, Etsuro Mori, Teruyuki Hirano, Toshimitsu Hamasaki, Takenori Yamaguchi Source Type: research
Multicenter prospective analysis of stroke patients taking oral anticoagulants: The PASTA registry - Study design and characteristics
The management of atrial fibrillation and deep venous thrombosis has evolved with the development of direct oral anticoagulants (DOAC), and oral anticoagulant (OAC) might influence the development or clinical course in both ischemic and hemorrhagic stroke. However, detailed data on the differences between the effects of the prior prescription of warfarin and DOAC on the clinical characteristics, neuroradiologic findings, and outcome of stroke are limited.
Source: Journal of Stroke and Cerebrovascular Diseases - October 28, 2019 Category: Neurology Authors: Satoshi Suda, Yasuyuki Iguchi, Shigeru Fujimoto, Yoshiki Yagita, Yu Kono, Masayuki Ueda, Kenichi Todo, Tomoyuki Kono, Takayuki Mizunari, Mineo Yamazaki, Takao Kanzawa, Seiji Okubo, Kimito Kondo, Nobuhito Nakajima, Takeshi Inoue, Takeshi Iwanaga, Makoto Na Source Type: research
Antithrombotic Drug Uses and Deep Intracerebral Hemorrhages in Stroke Patients With Deep Cerebral Microbleeds
Conclusions: Multivariate analysis revealed that the use of antiplatelet drugs or warfarin did not significantly influence the occurrence of deep ICH in patients with deep MBs. Antiplatelet drugs or warfarin did not significantly elevate the rate of deep ICHs in stroke patients with pre-existing deep MBs.
Source: Journal of Stroke and Cerebrovascular Diseases - September 10, 2012 Category: Neurology Authors: Toshio Imaizumi, Shigeru Inamura, Ikuhide Kohama, Kazuhisa Yoshifuji, Tatsufumi Nomura, Katsuya Komatsu Tags: Original Articles Source Type: research
Protocol for Cerebral Microbleeds During the Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients With Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial
Anticoagulants are widely used to prevent recurrence of ischemic stroke in patients with nonvalvular atrial fibrillation, but in some patients, they also cause bleeding, particularly intracranial hemorrhage. One of the independent predictors of intracerebral hemorrhage is the presence of cerebral microbleeds (CMBs); a high incidence of intracerebral hemorrhage is reported in warfarin-treated patients with multiple CMBs. Longitudinal study suggested that the presence of CMBs at baseline is a predictor of new CMBs in warfarin-treated patients.
Source: Journal of Stroke and Cerebrovascular Diseases - July 4, 2015 Category: Neurology Authors: Shunya Takizawa, Fumiaki Tanaka, Kazutoshi Nishiyama, Yasuhiro Hasegawa, Eiichiro Nagata, Atsushi Mizuma, Sachiko Yutani, Taira Nakayama, Hiroyuki Kobayashi, Noriharu Yanagimachi, Takashi Okazaki, Kazuo Kitagawa, CMB-NOW Study Investigators Source Type: research
Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry
Prior ischemic stroke or transient ischemic attack (TIA) is a high risk for thromboembolism in patients with nonvalvular atrial fibrillation (NVAF). To clarify rates of thromboembolic and hemorrhagic events, and target intensities of warfarin for secondary prevention, a subanalysis was performed using data from the J-RHYTHM Registry.
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2015 Category: Neurology Authors: Eitaro Kodani, Hirotsugu Atarashi, Hiroshi Inoue, Ken Okumura, Takeshi Yamashita, Hideki Origasa, J-RHYTHM Registry Investigators Source Type: research
Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR
Current guidelines allow the administration of intravenous recombinant tissue plasminogen activator (IV r-tPA) to warfarin-treated patients with acute ischemic stroke (AIS) who have an international normalized ratio (INR) of ≤1.7. However, concerns remain about the safety of using IV r-tPA in this situation due to a conceivable risk of symptomatic intracranial hemorrhage (sICH), lack of dedicated randomized controlled trials and the conflicts in the available data. We aimed to determine the risk of sICH in warfarin-tr eated patients with subtherapeutic INR who received IV r-tPA for AIS in our large volume comprehensive center.
Source: Journal of Stroke and Cerebrovascular Diseases - February 25, 2021 Category: Neurology Authors: Ashkan Mowla, Aurangzeb Memon, Seyed-Mostafa Razavi, Navdeep S. Lail, Caila B. Vaughn, Pegah Mohammadi, Robert N. Sawyer, Peyman Shirani Source Type: research
Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction
Convexity subarachnoid hemorrhage (cSAH) is typically due to head trauma, but various nontraumatic causes for cSAH are known also. Nontraumatic cSAH is most commonly associated with cerebral amyloid angiopathy (CAA) in the elderly or with reversible cerebral vasoconstriction syndrome in younger subjects,1 but cSAH rarely occurs subsequent to acute ischemic stroke.2 Direct oral anticoagulants (DOACs) are used to reduce the risk of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation and have favorable bleeding profiles as compared with warfarin,3,4 but here we describe 2 cSAH patients who ...
Source: Journal of Stroke and Cerebrovascular Diseases - August 13, 2020 Category: Neurology Authors: Yoichiro Sugita, Yoichiro Nishida, Satoru Ishibashi, Takanori Yokota Tags: Case Report Source Type: research
Net Clinical Benefit of Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation: A Subgroup Analysis of J-ROCKET AF
Conclusion: Analysis of the NCB supports that rivaroxaban therapy provides clinical benefit for Japanese patients with AF.
Source: Journal of Stroke and Cerebrovascular Diseases - November 4, 2013 Category: Neurology Authors: Shinichiro Uchiyama, Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuma Iekushi, Satoshi Yamanaka, Masahiro Tajiri, J-ROCKET AF Study Tags: Original Articles Source Type: research
Incidence, Mortality, and Risk Factors for Oral Anticoagulant–associated Intracranial Hemorrhage in Patients with Atrial Fibrillation
Warfarin, a vitamin K epoxide reductase inhibitor, is the oral anticoagulant most commonly used to reduce the risk of stroke in patients with atrial fibrillation (AF). Warfarin has proved to be efficacious for this purpose in multiple clinical trials. However, warfarin use is laborious and associated with an increased risk of intracranial hemorrhage (ICH). Various factors increase the risk of warfarin-related ICH, including older age, intensity of anticoagulation, hypertension, and history of cerebrovascular disease.
Source: Journal of Stroke and Cerebrovascular Diseases - October 29, 2014 Category: Neurology Authors: Rebbeca Grysiewicz, Philip B. Gorelick Tags: Review Article Source Type: research
Anticoagulant's character: Hemorrhagic vs. ischemic stroke
【Background】Anticoagulants have switched from warfarin to direct oral anticoagulants (DOACs) because they are believed to have more effects and lower hemorrhagic risks. However, intracranial hemorrhage really occurs in patients treated with DOACs.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Tatsuya Koike, Takahisa Mori, Kazuhiro Yoshioka, Yuhei Tanno, Shigen Kasakura, Noriyoshi Nakai Source Type: research
Secular Trends in the Background of Intracerebral Hemorrhage from 2010 to 2015
Direct oral anticoagulants (DOACs) were recently introduced for the clinical use in stroke prevention, and they are reported to show a lower risk of intracerebral hemorrhage (ICH) compared to warfarin. We were interested to know whether there is any change in clinical backgrounds of ICH patients to date.
Source: Journal of Stroke and Cerebrovascular Diseases - October 6, 2018 Category: Neurology Authors: Taizen Nakase, Junta Moroi, Tatsuya Ishikawa Source Type: research
